Jaguar Leaf imageWe are committed to
discovering, developing, and
commercializing plant-based
prescription medicines for
urgent global health needs.
Bringing Plant-based
Medicines to Life™
Jaguar HealthOUR MISSION
Jaguar Leaf LogoJaguar HealthBringing Plant-based
Medicines to Life™
We are committed to discovering,
developing, and commercializing
plant-based prescription medicines
for urgent global health needs.
OUR MISSION
Pipeline Icon

Learn About Our Key
Near-Term Milestones

Top line results expected in Q1 2024 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.

We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.

Forest image
Pipeline Icon

Learn About Our Key Near-Term Milestones

Top line results expected in Q1 2024 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.

We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.

Sustainability Icon

Advancing Sustainability and
Community Benefit Sharing

We are dedicated to supporting sustainability and local communities as we develop first-in-class, plant-based prescription medicines to address unmet medical needs for people globally.

Image of human hand with plant
Sustainability Icon

Advancing Sustainability and
Community Benefit Sharing

We are dedicated to supporting sustainability and local communities as we develop first-in-class, plant-based prescription medicines to address unmet medical needs for people globally.

Plant to Product Pipeline

Delivering Solutions With
Our Novel, Plant-based Pipeline

Our product portfolio addresses multiple indications for gastrointestinal (GI) diseases, spanning multiple stages of development from preclinical to commercial approval.

Image of flowing plant
Plant to Product Pipeline

Delivering Solutions With
Our Novel, Plant-based Pipeline

Our product portfolio addresses multiple indications for gastrointestinal (GI) diseases, spanning multiple stages of development from preclinical to commercial approval.